Resource Center

Sep 5, 2019
  |  Presentation

Utilizing DILIsym, a QST Platform, to Extract More from Your Data to Support Decisions

Recently Completed Clinical Trial Indicates that DILIsym Backup Compound Predictions Were Correct

  • DILIsym simulations suggested that the backup compound is considerably less likely to pose a DILI risk than the lead compound at the proposed clinical dosing regimens
  • No liver signals reported for any dosing regimes for the backup compound in clinical trial completed in 2018
  • Combination of predicted and measured safety have enabled sponsor to confidently continue clinical development of the backup compound

Contact Us About This Presentation